Evidence map›Paper›PMID 42579202›Full record

ArticleCell regeneration (London, England)2026

Small-molecule cocktail 2SM promotes heart regeneration via inducing embryonic-like cardiomyocyte state.

Zihao Wang, Lixia Zheng, Xiaokai Ma, Peng Gao, Yuanyuan Chen, Chenglu Xiao, Xin Zhao, Zhenyan Xiao, Xiaojun Zhu, Zhe Zhang and 1 more

Abstract read
In one paragraph

Article in Cell regeneration (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zihao WangBeijing Key Laboratory of Cardiometabolic Molecular Medicine, Institute of Molecular Medicine, and College of Future Technology, Peking University, Beijing, 100871, China.
Lixia ZhengSchool of Basic Medical Sciences, The Second Affiliated Hospital, Institute of Biomedical Innovation, The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Jiangxi Medical College, Nanchang University, Nanchang, 330031, China. zhenglixia@ncu.edu.cn.
Xiaokai MaBeijing Key Laboratory of Cardiometabolic Molecular Medicine, Institute of Molecular Medicine, and College of Future Technology, Peking University, Beijing, 100871, China.
Peng GaoBeijing Key Laboratory of Cardiometabolic Molecular Medicine, Institute of Molecular Medicine, and College of Future Technology, Peking University, Beijing, 100871, China.
Yuanyuan ChenBeijing Key Laboratory of Cardiometabolic Molecular Medicine, Institute of Molecular Medicine, and College of Future Technology, Peking University, Beijing, 100871, China.
Chenglu XiaoSchool of Basic Medical Sciences, The Second Affiliated Hospital, Institute of Biomedical Innovation, The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Jiangxi Medical College, Nanchang University, Nanchang, 330031, China.
Xin ZhaoSchool of Basic Medical Sciences, The Second Affiliated Hospital, Institute of Biomedical Innovation, The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Jiangxi Medical College, Nanchang University, Nanchang, 330031, China.
Zhenyan XiaoSchool of Basic Medical Sciences, The Second Affiliated Hospital, Institute of Biomedical Innovation, The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Jiangxi Medical College, Nanchang University, Nanchang, 330031, China.
Xiaojun ZhuBeijing Key Laboratory of Cardiometabolic Molecular Medicine, Institute of Molecular Medicine, and College of Future Technology, Peking University, Beijing, 100871, China.
Zhe ZhangDivision of Cardiac Surgery, The Third Hospital of Peking University, Beijing, 100083, China.
Jing-Wei XiongBeijing Key Laboratory of Cardiometabolic Molecular Medicine, Institute of Molecular Medicine, and College of Future Technology, Peking University, Beijing, 100871, China. jingwei_xiong@pku.edu.cn.ORCID http://orcid.org/0000-0001-8438-4782

Funding

GanPo Senior Investigator Award, Jiangxi Province gpyc20240020National Key R&D Program of China 2018YFA0800501National Key R&D Program of China 2023YFA1800600National Natural Science Foundation of China 32230032National Natural Science Foundation of China 82400316
6 · The paper itself

Abstract

Adult mammalian cardiomyocytes exhibit limited regenerative capacity, which remains a major challenge for functional recovery after myocardial infarction (MI). Our previous study identified a cocktail of five small molecules (5SM) that promotes cardiomyocyte proliferation and heart regeneration; however, the complexity of this five-compound mixture poses significant barriers to clinical translation and mechanistic studies. Here, we identified a simplified dual-compound cocktail (2SM) composed of phenylephrine hydrochloride (PE) and harmine (HM), which also robustly enhanced cardiomyocyte proliferation in vitro and in vivo. Transcriptomic and metabolomic analyses indicated that 2SM treatment activated cardiomyocyte cell-cycle programs and metabolic reprogramming. PE activated a fetal program and contributed to the up-regulation of CCND1 and WEE1 by activating mTOR signaling pathway, thus enabling cardiomyocytes to enter the G1/S phase but not G2/M phase. HM inhibited DYRK1A and activated MMB and FOXM1-MuvB complex, resulting in the upregulation of G2/M phase gene expression, of which the upregulated CDC25 proteins dephosphorylate CDK1, thereby relieving the inhibitory effect of PE. Sequential treatment of PE followed by HM was essential for completion of cytokinesis. In summary, we identified that 2SM, two compounds of 5SM, reprogrammed cardiomyocytes into an embryonic-like state, and precisely coordinated cell cycle progression for promoting cardiomyocyte proliferation.

Indexed as

Cardiomyocyte proliferationHeart regenerationSmall molecule

Identifiers

PMID42579202
PMCPMC13457617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.